Comparing two PET tracers for recurrent MTC
Part of Cancer clinical trials.
This study compares a new imaging agent called 68Ga-MGS5 with the standard agent 68Ga-DOTATATE to see which one better detects recurrent medullary thyroid carcinoma on a PET/CT scan. The goal is to improve tumor detection in people whose MTC has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with medullary thyroid carcinoma (MTC).
- Your MTC has come back after treatment (recurrence).
- You are not pregnant or breastfeeding (if applicable).
- You are not severely claustrophobic and can undergo a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
This trial compares two types of PET scans to see which one better detects neuroendocrine tumors (rare cancers that grow slowly in the body). You'll receive both scans to help doctors understand which imaging method works best.
This study tests a new type of PET scan to find thyroid cancer that has come back or spread. It compares two tracers to see which one better shows the cancer, which may help doctors choose the right treatment.
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
Hear when a new Medullary Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.